Monitoring real‐life utilization of pembrolizumab in advanced melanoma using the Portuguese National Cancer Registry-Reference-Cited by-同舟云学术

Monitoring real‐life utilization of pembrolizumab in advanced melanoma using the Portuguese National Cancer Registry

Published:2020-11-09 Issue:3 Volume:30 Page:342-349
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Borges Fábio C.¹^ORCID,Ramos Catarina¹,Ramos Adriana¹,Mendes Gonçalo P.¹,Murteira Rodrigo¹,Soares Patrícia¹,Furtado Claudia²,Miranda Ana C.¹,Costa Filipa A.¹^ORCID,

Affiliation:

1. Registo Oncológico Nacional (RON), Instituto Português de Oncologia de Lisboa Francisco Gentil Lisboa Portugal

2. Health Technology Assessment, Pricing and Reimbursement Division (DATS), INFARMED, Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. Lisboa Portugal

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.5163

Reference23 articles.

1. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma

3. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

4. Utilizing Patient Registries as Health Technology Assessment (HTA) tool

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Malignant melanoma in Portuguese adult population: a scoping review of the real-world evidence;Clinical and Translational Oncology;2024-07-16

2. Real-world effectiveness of aromatase inhibitors and fulvestrant in HR+/HER2- advanced breast cancer: a snapshot of the last two years before conventional use of CDK 4/6 inhibitors in a Portuguese institution;Journal of Pharmaceutical Policy and Practice;2024-01-17

3. Coincidence of primary adrenocortical carcinoma and melanoma: three CASE reports;BMC Endocrine Disorders;2023-01-06